Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Xponance Inc.

Xponance Inc. lowered its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 11.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 19,433 shares of the company’s stock after selling 2,406 shares during the quarter. Xponance Inc.’s holdings in Henry Schein were worth $1,471,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Baystate Wealth Management LLC increased its stake in Henry Schein by 2,500.0% during the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock worth $39,000 after buying an additional 500 shares during the period. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Henry Schein during the fourth quarter worth about $39,000. Neo Ivy Capital Management acquired a new position in shares of Henry Schein in the third quarter worth about $46,000. Covestor Ltd boosted its holdings in Henry Schein by 22.8% in the third quarter. Covestor Ltd now owns 1,367 shares of the company’s stock valued at $102,000 after purchasing an additional 254 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in Henry Schein by 14.3% during the 3rd quarter. Fifth Third Bancorp now owns 1,744 shares of the company’s stock valued at $129,000 after purchasing an additional 218 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on HSIC shares. JPMorgan Chase & Co. upped their target price on Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Barrington Research raised their price objective on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Leerink Partnrs reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. TheStreet raised shares of Henry Schein from a “c+” rating to a “b-” rating in a research report on Monday, February 26th. Finally, Piper Sandler lifted their price target on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $81.09.

Henry Schein Stock Up 0.6 %

Shares of Henry Schein stock opened at $73.21 on Thursday. The stock has a market capitalization of $9.41 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 1.79 and a beta of 0.87. The business’s 50 day simple moving average is $74.29 and its 200-day simple moving average is $72.43. The company has a current ratio of 1.67, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. Henry Schein, Inc. has a twelve month low of $60.01 and a twelve month high of $85.39.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. During the same quarter last year, the company posted $1.21 EPS. Henry Schein’s revenue for the quarter was down 10.5% on a year-over-year basis. Equities research analysts forecast that Henry Schein, Inc. will post 5.07 earnings per share for the current year.

Insider Activity at Henry Schein

In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.